Daiichi Sankyo Launches Anti-Clotting Drug In France, Italy
This article was originally published in PharmAsia News
Daiichi Sankyo has launched its newly approved Effient (prasugrel) in France and Italy, expanding its reach to 22 nations to prevent blood clotting
You may also be interested in...
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
As American auto giants GM and Ford take the wheel on working with ventilator manufacturers to make the critically needed devices during the COVID-19 pandemic, two longtime quality experts explain where the device and auto companies will find common ground when it comes to quality systems.
Despite a reprieve last summer from the Trump administration’s proposed drug price rebate rule, speakers at the 25th annual Pharmacy Benefit Manager Institute kept the focus on price transparency and talked up new ways to manage drug costs for patients in need of treatment.